Uteroglobin

Drug Profile

Uteroglobin

Alternative Names: Blastokinin; CC10; CC16; CCSP; CG 100; CG 367; CG201; CG459; Clara cell 10 kDa protein; Claragen; PCB-binding protein; Recombinant human CC10 protein; Recombinant human Clara cell 10 kDa protein; Recombinant human secretoglobin 1A1; rhCC10; SCGB1A1; Urine protein-1

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Brigham and Womens Hospital; Therabron Therapeutics; Tufts-New England Medical Center
  • Class Anti-inflammatories; Recombinant proteins; Respiratory stimulants
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia; Bronchiolitis obliterans
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia
  • Phase I/II Sinusitis
  • Preclinical Bronchiolitis obliterans
  • No development reported Acute lung injury; Asthma; Burns; Chronic obstructive pulmonary disease; Influenza virus infections; Pneumonia; Respiratory distress syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Burns in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top